A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies
The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment....
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Zhou, Wenhao [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Neuro-Brucellosis - Gouider, R. ELSEVIER, 2015, an international journal devoted to all branches of analytical chemistry, Amsterdam |
|---|---|
| Übergeordnetes Werk: |
volume:1238 ; year:2023 ; day:15 ; month:01 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.aca.2022.340633 |
|---|
| Katalog-ID: |
ELV059751819 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV059751819 | ||
| 003 | DE-627 | ||
| 005 | 20230626053842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221219s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.aca.2022.340633 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001983.pica |
| 035 | |a (DE-627)ELV059751819 | ||
| 035 | |a (ELSEVIER)S0003-2670(22)01204-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.10 |2 bkl | ||
| 100 | 1 | |a Zhou, Wenhao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies |
| 264 | 1 | |c 2023transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. | ||
| 520 | |a The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. | ||
| 650 | 7 | |a Luciferase immunoprecipitation system |2 Elsevier | |
| 650 | 7 | |a Antibody detection |2 Elsevier | |
| 650 | 7 | |a SARS-CoV-2 |2 Elsevier | |
| 650 | 7 | |a Gaussia luciferase |2 Elsevier | |
| 650 | 7 | |a Receptor binding domain |2 Elsevier | |
| 700 | 1 | |a He, Ping |4 oth | |
| 700 | 1 | |a Liu, Huan |4 oth | |
| 700 | 1 | |a Wei, Hongping |4 oth | |
| 700 | 1 | |a Yu, Junping |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Gouider, R. ELSEVIER |t Neuro-Brucellosis |d 2015 |d an international journal devoted to all branches of analytical chemistry |g Amsterdam |w (DE-627)ELV013501887 |
| 773 | 1 | 8 | |g volume:1238 |g year:2023 |g day:15 |g month:01 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.aca.2022.340633 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_120 | ||
| 936 | b | k | |a 35.10 |j Physikalische Chemie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 1238 |j 2023 |b 15 |c 0115 |h 0 | ||
| author_variant |
w z wz |
|---|---|
| matchkey_str |
zhouwenhaohepingliuhuanweihongpingyujunp:2023----:lcfrsbsduoaeasyorpdnsniieeet |
| hierarchy_sort_str |
2023transfer abstract |
| bklnumber |
35.10 |
| publishDate |
2023 |
| allfields |
10.1016/j.aca.2022.340633 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001983.pica (DE-627)ELV059751819 (ELSEVIER)S0003-2670(22)01204-1 DE-627 ger DE-627 rakwb eng 610 VZ 540 VZ 35.10 bkl Zhou, Wenhao verfasserin aut A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies 2023transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. Luciferase immunoprecipitation system Elsevier Antibody detection Elsevier SARS-CoV-2 Elsevier Gaussia luciferase Elsevier Receptor binding domain Elsevier He, Ping oth Liu, Huan oth Wei, Hongping oth Yu, Junping oth Enthalten in Elsevier Science Gouider, R. ELSEVIER Neuro-Brucellosis 2015 an international journal devoted to all branches of analytical chemistry Amsterdam (DE-627)ELV013501887 volume:1238 year:2023 day:15 month:01 pages:0 https://doi.org/10.1016/j.aca.2022.340633 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_120 35.10 Physikalische Chemie: Allgemeines VZ AR 1238 2023 15 0115 0 |
| spelling |
10.1016/j.aca.2022.340633 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001983.pica (DE-627)ELV059751819 (ELSEVIER)S0003-2670(22)01204-1 DE-627 ger DE-627 rakwb eng 610 VZ 540 VZ 35.10 bkl Zhou, Wenhao verfasserin aut A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies 2023transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. Luciferase immunoprecipitation system Elsevier Antibody detection Elsevier SARS-CoV-2 Elsevier Gaussia luciferase Elsevier Receptor binding domain Elsevier He, Ping oth Liu, Huan oth Wei, Hongping oth Yu, Junping oth Enthalten in Elsevier Science Gouider, R. ELSEVIER Neuro-Brucellosis 2015 an international journal devoted to all branches of analytical chemistry Amsterdam (DE-627)ELV013501887 volume:1238 year:2023 day:15 month:01 pages:0 https://doi.org/10.1016/j.aca.2022.340633 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_120 35.10 Physikalische Chemie: Allgemeines VZ AR 1238 2023 15 0115 0 |
| allfields_unstemmed |
10.1016/j.aca.2022.340633 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001983.pica (DE-627)ELV059751819 (ELSEVIER)S0003-2670(22)01204-1 DE-627 ger DE-627 rakwb eng 610 VZ 540 VZ 35.10 bkl Zhou, Wenhao verfasserin aut A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies 2023transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. Luciferase immunoprecipitation system Elsevier Antibody detection Elsevier SARS-CoV-2 Elsevier Gaussia luciferase Elsevier Receptor binding domain Elsevier He, Ping oth Liu, Huan oth Wei, Hongping oth Yu, Junping oth Enthalten in Elsevier Science Gouider, R. ELSEVIER Neuro-Brucellosis 2015 an international journal devoted to all branches of analytical chemistry Amsterdam (DE-627)ELV013501887 volume:1238 year:2023 day:15 month:01 pages:0 https://doi.org/10.1016/j.aca.2022.340633 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_120 35.10 Physikalische Chemie: Allgemeines VZ AR 1238 2023 15 0115 0 |
| allfieldsGer |
10.1016/j.aca.2022.340633 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001983.pica (DE-627)ELV059751819 (ELSEVIER)S0003-2670(22)01204-1 DE-627 ger DE-627 rakwb eng 610 VZ 540 VZ 35.10 bkl Zhou, Wenhao verfasserin aut A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies 2023transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. Luciferase immunoprecipitation system Elsevier Antibody detection Elsevier SARS-CoV-2 Elsevier Gaussia luciferase Elsevier Receptor binding domain Elsevier He, Ping oth Liu, Huan oth Wei, Hongping oth Yu, Junping oth Enthalten in Elsevier Science Gouider, R. ELSEVIER Neuro-Brucellosis 2015 an international journal devoted to all branches of analytical chemistry Amsterdam (DE-627)ELV013501887 volume:1238 year:2023 day:15 month:01 pages:0 https://doi.org/10.1016/j.aca.2022.340633 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_120 35.10 Physikalische Chemie: Allgemeines VZ AR 1238 2023 15 0115 0 |
| allfieldsSound |
10.1016/j.aca.2022.340633 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001983.pica (DE-627)ELV059751819 (ELSEVIER)S0003-2670(22)01204-1 DE-627 ger DE-627 rakwb eng 610 VZ 540 VZ 35.10 bkl Zhou, Wenhao verfasserin aut A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies 2023transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. Luciferase immunoprecipitation system Elsevier Antibody detection Elsevier SARS-CoV-2 Elsevier Gaussia luciferase Elsevier Receptor binding domain Elsevier He, Ping oth Liu, Huan oth Wei, Hongping oth Yu, Junping oth Enthalten in Elsevier Science Gouider, R. ELSEVIER Neuro-Brucellosis 2015 an international journal devoted to all branches of analytical chemistry Amsterdam (DE-627)ELV013501887 volume:1238 year:2023 day:15 month:01 pages:0 https://doi.org/10.1016/j.aca.2022.340633 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_120 35.10 Physikalische Chemie: Allgemeines VZ AR 1238 2023 15 0115 0 |
| language |
English |
| source |
Enthalten in Neuro-Brucellosis Amsterdam volume:1238 year:2023 day:15 month:01 pages:0 |
| sourceStr |
Enthalten in Neuro-Brucellosis Amsterdam volume:1238 year:2023 day:15 month:01 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Physikalische Chemie: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Luciferase immunoprecipitation system Antibody detection SARS-CoV-2 Gaussia luciferase Receptor binding domain |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Neuro-Brucellosis |
| authorswithroles_txt_mv |
Zhou, Wenhao @@aut@@ He, Ping @@oth@@ Liu, Huan @@oth@@ Wei, Hongping @@oth@@ Yu, Junping @@oth@@ |
| publishDateDaySort_date |
2023-01-15T00:00:00Z |
| hierarchy_top_id |
ELV013501887 |
| dewey-sort |
3610 |
| id |
ELV059751819 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV059751819</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626053842.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221219s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.aca.2022.340633</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001983.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV059751819</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0003-2670(22)01204-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zhou, Wenhao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Luciferase immunoprecipitation system</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antibody detection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SARS-CoV-2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gaussia luciferase</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Receptor binding domain</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">He, Ping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Huan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wei, Hongping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Junping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Gouider, R. ELSEVIER</subfield><subfield code="t">Neuro-Brucellosis</subfield><subfield code="d">2015</subfield><subfield code="d">an international journal devoted to all branches of analytical chemistry</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV013501887</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1238</subfield><subfield code="g">year:2023</subfield><subfield code="g">day:15</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.aca.2022.340633</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.10</subfield><subfield code="j">Physikalische Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1238</subfield><subfield code="j">2023</subfield><subfield code="b">15</subfield><subfield code="c">0115</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Zhou, Wenhao |
| spellingShingle |
Zhou, Wenhao ddc 610 ddc 540 bkl 35.10 Elsevier Luciferase immunoprecipitation system Elsevier Antibody detection Elsevier SARS-CoV-2 Elsevier Gaussia luciferase Elsevier Receptor binding domain A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies |
| authorStr |
Zhou, Wenhao |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013501887 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 540 VZ 35.10 bkl A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies Luciferase immunoprecipitation system Elsevier Antibody detection Elsevier SARS-CoV-2 Elsevier Gaussia luciferase Elsevier Receptor binding domain Elsevier |
| topic |
ddc 610 ddc 540 bkl 35.10 Elsevier Luciferase immunoprecipitation system Elsevier Antibody detection Elsevier SARS-CoV-2 Elsevier Gaussia luciferase Elsevier Receptor binding domain |
| topic_unstemmed |
ddc 610 ddc 540 bkl 35.10 Elsevier Luciferase immunoprecipitation system Elsevier Antibody detection Elsevier SARS-CoV-2 Elsevier Gaussia luciferase Elsevier Receptor binding domain |
| topic_browse |
ddc 610 ddc 540 bkl 35.10 Elsevier Luciferase immunoprecipitation system Elsevier Antibody detection Elsevier SARS-CoV-2 Elsevier Gaussia luciferase Elsevier Receptor binding domain |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
p h ph h l hl h w hw j y jy |
| hierarchy_parent_title |
Neuro-Brucellosis |
| hierarchy_parent_id |
ELV013501887 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry |
| hierarchy_top_title |
Neuro-Brucellosis |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013501887 |
| title |
A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies |
| ctrlnum |
(DE-627)ELV059751819 (ELSEVIER)S0003-2670(22)01204-1 |
| title_full |
A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies |
| author_sort |
Zhou, Wenhao |
| journal |
Neuro-Brucellosis |
| journalStr |
Neuro-Brucellosis |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Zhou, Wenhao |
| container_volume |
1238 |
| class |
610 VZ 540 VZ 35.10 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Zhou, Wenhao |
| doi_str_mv |
10.1016/j.aca.2022.340633 |
| dewey-full |
610 540 |
| title_sort |
a luciferase based automated assay for rapid and sensitive detection of sars-cov-2 antibodies |
| title_auth |
A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies |
| abstract |
The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. |
| abstractGer |
The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. |
| abstract_unstemmed |
The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_40 GBV_ILN_120 |
| title_short |
A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies |
| url |
https://doi.org/10.1016/j.aca.2022.340633 |
| remote_bool |
true |
| author2 |
He, Ping Liu, Huan Wei, Hongping Yu, Junping |
| author2Str |
He, Ping Liu, Huan Wei, Hongping Yu, Junping |
| ppnlink |
ELV013501887 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.aca.2022.340633 |
| up_date |
2024-07-06T22:56:55.174Z |
| _version_ |
1803872229313740800 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV059751819</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626053842.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221219s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.aca.2022.340633</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001983.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV059751819</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0003-2670(22)01204-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zhou, Wenhao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The Coronavirus disease 2019 (COVID-19) pandemic brings great challenges to the public health and social economics around the world. As the pandemic continues and the mass vaccination goes on, monitoring the antibodies is particularly important for the epidemiological survey and vaccine assessment. Here, we developed a luciferase immunoprecipitation assay combined with an automated platform to detect anti-Receptor Binding Domain (RBD) antibody, where protein A and protein G modified magnetic beads were used to capture antibodies in serum samples and SARS-CoV-2 RBD was fused with Gaussia luciferase to label the captured target antibodies. The whole detection procedure can be completed within 20 min. The developed assay has proven up to 32 times more sensitive than ELISA for the detection of RBD antibodies. Furthermore, the results of the antibody detection of sera from vaccination as well as convalescence displayed good performance. The automated platform may provide a powerful tool for the control of COVID-19 pandemic by vaccination and the research of SARS-CoV-2 seroconversion.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Luciferase immunoprecipitation system</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antibody detection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SARS-CoV-2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gaussia luciferase</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Receptor binding domain</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">He, Ping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Huan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wei, Hongping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Junping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Gouider, R. ELSEVIER</subfield><subfield code="t">Neuro-Brucellosis</subfield><subfield code="d">2015</subfield><subfield code="d">an international journal devoted to all branches of analytical chemistry</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV013501887</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1238</subfield><subfield code="g">year:2023</subfield><subfield code="g">day:15</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.aca.2022.340633</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.10</subfield><subfield code="j">Physikalische Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1238</subfield><subfield code="j">2023</subfield><subfield code="b">15</subfield><subfield code="c">0115</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.399295 |